camrelizumab + apatinib

Camrelizumab + apatinib is a combination therapy consisting of two agents with complementary mechanisms of action for the treatment of various advanced malignancies. Camrelizumab is a humanized monoclonal antibody targeting programmed cell death protein 1 (PD-1), functioning as an immune checkpoint inhibitor to enhance T-cell mediated antitumor immunity. Apatinib is a small molecule tyrosine kinase inhibitor that selectively inhibits vascular endothelial growth factor receptor 2 (VEGFR2), thereby blocking angiogenesis and tumor blood supply. The combination has demonstrated promising antitumor activity and manageable toxicity in multiple cancer types, including hepatocellular carcinoma, primary liver cancer, non-small cell lung cancer, recurrent/metastatic nasopharyngeal carcinoma, cervical cancer, and gastric cancer[1][2][3][4][5][6]. This regimen leverages the synergistic effects of immunotherapy and antiangiogenic therapy to improve clinical outcomes in patients with advanced or refractory cancers.

Brand names

AiRuiKa (for camrelizumab)Aitan (for apatinib)AiRuiKa + Aitan

Other names

SHR1210 (camrelizumab)Rivoceranib (apatinib, international nonproprietary name)